<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451578</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00086021</org_study_id>
    <nct_id>NCT03451578</nct_id>
  </id_info>
  <brief_title>Alpha MSH in Ocular Disease</brief_title>
  <official_title>The Role of Alpha Melanocyte Stimulating Hormone in Ocular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is gain a better understanding of a molecule called alpha
      melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease.
      Alpha MSH has been shown to have an important role in the regulation of ocular immunity in
      animal models of inflammatory retinal diseases and retinal dystrophies, and there may be a
      protective effect of alpha MSH. By studying the levels of alpha MSH in your eye we may better
      understand its role in advanced dry macular degeneration. By studying the levels of this
      molecule we hope to better understand if it may be a good target for future treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A small amount (0.1 mL) of aqueous humor would be removed from the study eye in the clinic
      setting. This sample will be processed and then sent off for measurement of alpha MSH levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of alpha melanocyte stimulating hormone as measured by enzyme-linked immunosorbent assay</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Dry Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Advanced Dry macular degeneration</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alpha MSH assay</intervention_name>
    <description>Assay to detect levels of alpha MSH in intraocular fluid.</description>
    <arm_group_label>Advanced Dry macular degeneration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  60 years or older

          -  diagnosis of advanced dry macular degeneration with foveal geographic atrophy

          -  limited vision or blindness (20/100 or worse) in that eye

          -  pseudophakia (prior cataract surgery in that eye)

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Fekrat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Eye Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Latoya Greene</last_name>
    <phone>919-684-9072</phone>
    <email>latoya.greene@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Latoya Greene</last_name>
      <phone>919-684-9072</phone>
      <email>laytoya.greene@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Sharon Fekrat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>macular degeneration</keyword>
  <keyword>blindness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanocyte-Stimulating Hormones</mesh_term>
    <mesh_term>alpha-MSH</mesh_term>
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
    <mesh_term>beta-Endorphin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

